The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging. METHODS: The authors assessed outcomes in 184 adult patients with HL who developed disease recurrence or progression after a matched related or unrelated allo-SCT at European Society for Blood and Marrow Transplantation-participating centers between 2010 and 2014. RESULTS: Eighty patients who received brentuximab vedotin (BV) salvage therapy were compared with 104 patients who did not. Patients in the BV group were younger (median age of 30 years vs 34 years) and were more likely to receive pretransplant BV (65% vs 46%) or posttransplant donor lymphocyte infusion (66% vs 33%). The 2 groups otherwise were comparable. Patients in the BV group received a median of 6 doses of posttransplant BV, resulting in a complete remission rate of 29%, a partial response rate of 45%, and a stable disease rate of 26%. Response to BV after allo-SCT did not appear to be affected by receipt of pretransplant BV. Despite a longer median follow-up for surviving patients in the BV group (33 months vs 23 months; P<.001), approximately 34% of the original BV cohort were alive and in CR at the time of last follow-up versus 18% in the group that did not receive BV (P=.003). The use of BV before donor lymphocyte infusion was found to
INTRODUCTION
Salvage chemotherapy and autologous stem cell transplantation (auto-SCT) result in the cure of approximately 50% of patients with Hodgkin lymphoma (HL) who fail first-line therapy. [1] [2] [3] [4] However, patients who develop disease progression after auto-SCT have a poor outcome, with a median overall survival (OS) of approximately 1 to 2 years. [5] [6] [7] [8] The use of brentuximab vedotin (BV) [9] [10] [11] or checkpoint inhibitors [12] [13] [14] in this setting is associated with a high rate of response; however, the majority of responses are not durable, with a median progression-free survival (PFS) of <1 year. Therefore, allogeneic SCT (allo-SCT) still is considered as a potentially curative and widely used treatment modality for patients with HL who progress after auto-SCT. [15] [16] [17] [18] [19] Unfortunately, only approximately 25% to 40% of patients who undergo allo-SCT after prior auto-SCT achieve long-term disease control.
For patients who develop disease recurrence or progression after allo-SCT, prognosis is dismal and treatment is challenging because the majority of these individuals are heavily pretreated and often have disease that is refractory to chemotherapy. 16, 17, [20] [21] [22] [23] Checkpoint inhibitors are increasingly being used in this setting and appear to be highly efficacious, although with conflicting safety results because they may be complicated by the rapid onset of severe and treatment-refractory graft-versus-host disease (GVHD). 24, 25 Anecdotal reports and a few small series have suggested that BV, either alone 26, 27 or combined with donor lymphocyte infusion (DLI), 28 may be efficacious in the post-allograft setting.
The purpose of the current study was to assess the safety and efficacy of BV when given as salvage treatment for HL recurrence after allo-SCT by comparing the outcome of patients who received BV salvage therapy with that of patients who did not receive BV salvage therapy, using a large sample from the European Society for Blood and Marrow Transplantation (EBMT) registry.
MATERIALS AND METHODS

Study Design and Data Collection
The current study was a retrospective, registry-based, multicenter analysis. Data were provided and approved for this study by the Lymphoma Working Party of the EBMT. The EBMT is a voluntary working group of >600 transplantation centers that are required to report all consecutive SCT and follow-up once a year. Audits are performed routinely to determine the accuracy of the data. Since January 1, 2003, all transplantation centers have been required to obtain written informed consent prior to data registration with the EBMT, following the Declaration of Helsinki of 1975.
Eligibility criteria for this analysis included adult patients (those aged >18 years) with classic HL who developed disease recurrence or progression after a first allo-SCT performed between 2010 and 2014 from an HLA-matched related or unrelated donor with bone marrow or peripheral blood stem cells. Patients who received cord blood, mismatched or haploidentical stem cells, and tandem transplantations were excluded.
Variables collected included recipient and donor age and sex; date of diagnosis; lines and detailed type of therapy prior to allo-SCT; response to each individual treatment line; previous auto-SCT; date, duration, and number of doses of pretransplantation BV; disease status at the time of transplantation (complete remission [CR], partial remission [PR], or active disease); performance status and comorbidity index; and transplantation-related factors including conditioning regimen, immunosuppression (in vivo T-cell depletion vs none), GVHD prophylaxis, stem cell source (bone marrow or peripheral blood), and donor type. Active disease was defined as not being in CR or PR, including stable disease (SD), primary induction failure, primary refractory disease, or disease progression. Finally, we collected the date of disease recurrence or progression after allo-SCT, the date of BV administration after allo-SCT, the duration and number of BV doses, the response to BV, additional cellular therapy such as DLI, acute and chronic GVHD, and disease status at the time of last follow-up.
Definitions
The histological diagnosis was based on local review, and patients were staged according to the Ann Arbor system. Disease status at the time of transplantation was classified as CR, PR, or active disease. Disease status was Cancer January 1, 2019 assessed by each investigator according to the Revised Response Criteria for Malignant Lymphoma 29 and to the institutional standard of care. The intensity of the conditioning regimens was defined as previously published. 17 
Statistical Analysis
Endpoints included response to BV, acute and chronic GVHD, and OS measured from the time of disease recurrence after allo-SCT. OS was defined as death from any cause. The probability of OS was calculated using the Kaplan-Meier estimator. Comparison of OS between patients who received BV within 60 days of disease recurrence and control patients was performed using a landmark curve starting at day 60 after disease recurrence. For all prognostic analyses, continuous variables were categorized and the median was used as the cutoff point. Univariate comparisons were performed using the log-rank test for OS. Use of BV after transplantation was analyzed as a time-dependent variable. A Cox proportional hazards model was used for multivariate regression. Factors known to influence the outcome and factors associated with a P value <.10 with any endpoint by univariate analysis were included in the model. Results were expressed as hazard ratios (HRs) with 95% confidence intervals (95% CIs). All tests were 2-sided. The type I error rate was fixed at 0.05 for the determination of factors associated with time-to-event outcomes.
All analyses were performed using R statistical software (version 3.1.1) with the R packages survival version 2.38, cmprsk version 2.2-7, and Hmisc version 3.16-0 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient and Transplantation Characteristics
A total of 184 patients met the eligibility criteria for the current study. The median age at the time of diagnosis and at allo-SCT was 27 years (interquartile range [IQR], 21-37 years) and 31 years (IQR, 25-40 years), respectively. The median age at the time of SCT according to donor type was 30 years (IQR, 24-38 years), and was 30 years (IQR, 22-39 years) for related and unrelated donors. Patients were heavily pretreated with a median of 4 lines of therapy (IQR, 1-9 lines) before allo-SCT. A total of 142 patients (77%) received prior auto-SCT. Disease status prior to auto-SCT was CR in 25% of patients, PR in 27% of patients, and active disease in 29% of patients. A total of 100 patients (54%) received BV prior to allo-SCT. Ninety-one patients (50%) had active disease at the time of allo-SCT. A total of 43 patients (23%) had a Karnofsky score ≤80. The median time from allo-SCT to disease recurrence was 7 months (range, 3-13 months). Eighty patients received BV as salvage therapy for disease recurrence/progression after allo-SCT (BV group) at a median of 67 days after disease recurrence (IQR, 29-300 days). These patients were compared with the remaining 104 patients who did not receive BV salvage therapy after allo-SCT (no BV group). The median follow-up after disease recurrence among surviving patients was 29 months (range, 14-38 months).
Comparisons of patients and transplantation characteristics between the 2 groups are shown in Table 1 and Table 2 , respectively.
Effect of Salvage BV Therapy After Allo-SCT
Patients in the BV group received a median of 6 doses of BV for disease recurrence after allo-SCT (range, 1-16 doses). Of the 58 patients in the BV group with available data regarding response, 17 patients (29%) achieved a CR, 26 patients (45%) achieved a PR, and 15 patients (26%) had SD ( Fig. 1 ). Response to BV after allo-SCT was not affected by whether patients had received BV (CR rate of 26%, PR rate of 48%, and SD rate of 26%) or had not received BV (CR rate of 37%, PR rate of 37%, and SD rate of 25%) before transplantation (Fig. 1 ). Response to BV was found to be highly predictive of disease status at the time of last follow-up (Fig. 2) . Indeed, of the 17 patients who achieved a CR after BV salvage therapy, 12 patients (71%) remained in CR at the time of last follow-up (Fig. 2) . For these patients, the median duration of BV therapy was 6 months and the median follow-up after BV was 30 months (Fig. 2) . Conversely, in the 26 patients who achieved a PR after BV salvage therapy, only 5 patients (19%) were in CR at the time of last follow-up (Fig. 2) . For these patients, the median duration of BV therapy was 5 months and the median followup after BV was 25 months (Fig. 2) . Finally, of 15 patients who achieved SD after BV salvage therapy, only 1 patient (7%) was in CR at the time of last follow-up (Fig. 2) . The median duration of BV therapy was 2 months only for these patients who achieved SD and the median followup after BV was 16 months (Fig. 2) . OS from the time of disease recurrence also was found to be highly influenced by response to BV, with a significantly better OS noted for responders (P=.007) (Fig. 3) . The outcomes of the 22 patients for whom data regarding response to BV were missing were not significantly different from the rest of the group (8 patients in CR and 12 patients still alive at the time of last follow-up) (Figs. 2 and 3) . Despite a longer median follow-up for surviving patients in the BV Cancer January 1, 2019 group (33 months vs 23 months; P<.001), approximately 34% of patients treated with BV were alive and in CR at the time of last follow-up versus 18% in the group that did not receive BV (P=.003).
Among 62 patients in the BV group with no evidence of chronic GVHD before disease recurrence, 22 patients (35%) developed chronic GVHD after disease recurrence. In the no-BV group, 23 of 82 patients with no evidence of chronic GVHD before disease recurrence (28%) developed chronic GVHD after disease recurrence. In univariate analysis, salvage BV therapy was not found to have any effect on chronic GVHD.
Donor Lymphocyte Infusion
In the current study cohort, DLI was administered to 66% of patients in the BV group compared with 33% of patients in the no-BV group. Of the 25 patients receiving BV before DLI, the median time from disease recurrence to BV therapy was 32 days (IQR, 14-60 days) and the median time between BV therapy and DLI was 98 days (IQR, 50-203 days). Of 25 patients receiving DLI before BV therapy, the median time from disease recurrence to DLI was 18 days (IQR, 0-65 days) and the median time between DLI and BV therapy was 302 days (IQR, 215-674 days). Of 34 patients receiving only DLI, the median Cancer January 1, 2019
time from disease recurrence to DLI was 1.34 months (IQR, 0.61-2.70 months). Of 29 patients receiving only BV, the median time from disease recurrence to BV therapy was 1.74 months (IQR, 0.89-6.32 months). In patients who were still alive at the time of last follow-up with no BV or DLI noted (20 patients), the median follow-up was 13.52 months after disease recurrence (IQR, 7.74-23.9 months). The probability of being alive and in Cancer January 1, 2019
CR at the time of last follow-up was 11% for 70 patients who did not receive either BV or DLI, 24% for 34 patients who received DLI without BV, 21% for 29 patients who received BV without DLI, 24% for 25 patients who received DLI followed by BV, and 40% for 25 patients who received BV followed by DLI (P=.003).
OS and Multivariate Analysis
The 1-year OS rate with a landmark curve starting at day 60 from disease recurrence after allo-SCT was 76% for patients who received BV within 60 days of disease recurrence versus 67% in the no-BV group (P=.13). In multivariate analysis, BV salvage therapy was not found to have any effect on OS for all patients, nor for the subgroups who received BV or not prior to allo-SCT. Older age and poor performance status at the time of allo-SCT adversely affected OS whereas receipt of DLI was found to significantly improve OS (Table 3) .
DISCUSSION
In the current study, we compared the outcomes of 80 patients with heavily pretreated HL who developed disease recurrence or progression after allo-SCT and received BV as salvage therapy with the outcomes of 104 similar patients who did not receive BV salvage therapy. In this challenging setting, BV therapy was found to result in an overall response rate (ORR) (CR plus PR) of 74% and a CR rate of 29%. It is interesting to note that the ORR to BV was not influenced by whether patients received or did not receive BV prior to undergoing allo-SCT, suggesting that rechallenge with BV can be advantageous in patients with HL who develop disease recurrence after allo-SCT, even if they had received BV before transplantation. The 1-year OS rate with a landmark curve starting at day 60 after disease recurrence Cancer January 1, 2019
after allo-SCT was encouraging (76%), even though it was not significantly different from the OS rate of 67% observed in 104 patients with HL who developed disease recurrence after allo-SCT but did not receive salvage BV therapy. Nevertheless, approximately 34% of patients in the BV group were alive and in CR at the time of last follow-up compared with only 18% in the group that did not receive BV (P=.003), despite a longer median followup for surviving patients in the BV group (33 months vs 23 months; P<.001). Unfortunately, given the registry nature of the current study, we were unable to gather information regarding the types of treatment used in the cohort that did not receive BV. These results strongly suggest that BV allowed for better disease control compared with the alternative salvage modalities used in the no-BV group. However, the disease status at the time of last follow-up also included the effect of all salvage therapies received. In 25 patients, BV was followed by DLI, which may have contributed toward response. Indeed, the use of BV before DLI was found to be associated with the highest probability of being alive in CR at the time of last follow-up. In the current study cohort, DLI was administered to 66% of patients in the BV group compared with 33% of patients in the no-BV group, indicating that the 2 dominant strategies were used for salvage therapy after allo-SCT: the combination of BV plus DLI or chemotherapy alone. Unfortunately, we do not know the reason for the higher frequency of DLI in the BV group, but one can speculate that DLI is used for the most part in responding patients after debulking and BV might have been more successful than alternative therapies in this regard. Tsirigotis et al reported on 16 patients with advanced HL who received BV after allo-SCT for active disease (13 patients) or as consolidation therapy (3 patients). 28 Ten of these patients also received DLI, resulting in GVHD in 7 patients. Among the 13 patients treated for active disease, CRs and PRs were observed in 7 patients and 2 patients, respectively, and the median PFS was 6 months. DLI may be added to BV therapy to achieve sustained disease control. In the current study, we did not observe any increase in de novo GVHD in the patients receiving BV, despite a significantly higher rate of DLI in this group. Indeed, BV may reduce GVHD by targeting CD30-positive T lymphocytes. 30 In that sense, we recently reported that, in multivariate analysis, BV treatment prior to allo-SCT was found to significantly decrease chronic GVHD.
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The treatment of patients with HL who develop disease recurrence or progression after allo-SCT remains a real challenge and an unmet medical need. 16, 17, [20] [21] [22] [23] Single agents or combination chemotherapy rarely are effective because the majority of these patients are heavily pretreated and often are resistant to chemotherapy, although encouraging results were reported with the use of bendamustine in patients who had not received it before.
31,32 DLI with or without prior chemotherapy resulted in a response rate of 43% to 56% at the expense of a rate of grade 2 to 4 GVHD of 32% to 38%. 15, 18, 33, 34 Currently, the most attractive treatment options for patients with HL who fail allo-SCT are BV with or without DLI or checkpoint inhibitors.
The results of the current study are in agreement with those of Gopal et al, who reported on a small cohort of 25 patients with heavily pretreated HL who received BV salvage therapy for disease recurrence after allo-SCT. 26 Approximately one-half of their evaluable patients achieved an objective response, and 38% attained a CR. The median PFS was 7.8 months and the median OS was not reached. Similarly, Carlo-Stella et al reported a small series of 16 patients with HL who received BV salvage therapy for disease recurrence after allo-SCT. 27 Five patients (31%) achieved a CR and 6 patients (38%) had a PR. After a median follow-up of 26 months, the median PFS, OS, and duration of response were 7 months, 25 months, and 5 months, respectively. In addition to the larger number of patients in the current study, one major difference between our study and those of Gopal et al 26 and Carlo-Stella et al 27 is that 64% of the 80 patients in the BV group in the current study had received BV before allo-SCT, whereas all patients in the studies by Gopal et al 26 and Carlo-Stella et al 27 were BV-naive. The results of the current study are in agreement with reported data regarding the efficacy of BV retreatment in patients who have received it earlier. 35 Another difference is that in the study by Gopal et al, 26 patients were excluded if they were within 100 days of allo-SCT or if they had active GVHD, thereby potentially eliminating the patients at highest risk.
Given the limited treatment options for patients with HL who develop disease recurrence after allo-SCT and the promising clinical and preclinical studies with checkpoint inhibitors, many clinicians are considering the off-label use of checkpoint inhibitors in this setting. Indeed, both nivolumab and pembrolizumab appear to be highly efficacious, but with conflicting results regarding whether their use frequently is complicated by the rapid onset of severe and treatment-refractory GVHD and on the influence of time from allo-SCT. Herbaux et al reported an ORR of 95% with single-agent nivolumab in 20 patients with HL who developed disease recurrence after allo-SCT. De novo GVHD occurred in 6 patients (30%), resulting in 2 deaths (10%). 24 In this study, nivolumab-induced GVHD was found to be strongly associated with the early initiation of nivolumab after allo-SCT. In another multicenter retrospective analysis, Haverkos et al reported an ORR of 77%, including a CR rate of 50% in 31 patients with lymphoma (29 of whom had HL) who were receiving nivolumab (28 patients) or pembrolizumab (3 patients) for disease recurrence after allo-SCT. 25 Unfortunately, 17 patients (55%) developed treatment-emergent GVHD, including grade 3 to 4 acute or severe chronic GVHD in 9 patients. Finally, 8 deaths (26%) related to new-onset GVHD were reported in this study. Based on these results, more data are needed regarding the use of checkpoint inhibitors after allo-SCT, and these agents cannot be recommended for routine use outside of a clinical trial. One important limitation of the current retrospective registry study is the risk of selection bias. Ideally, this question should be answered by a prospective randomized trial comparing BV and DLI with investigator choice in patients with HL who develop disease recurrence after allo-SCT. Stratification is needed regarding whether patients were or were not exposed to BV prior to undergoing allo-SCT. However, this type of study is ethically questionable because of the limited alternative options in these often chemoresistant patients, particularly with the potential for fatal toxicities after the use of checkpoint inhibitors.
The results of the current study indicate that BV is a safe and highly effective salvage therapy for patients with HL who develop disease recurrence or progression after undergoing allo-SCT, even after prior exposure to BV. Posttransplantation BV may synergize with immune interventions such as DLI to achieve sustained control of HL recurring after allo-SCT. Finally, these results also provide rationale for the upcoming French and German studies testing BV maintenance therapy after allo-SCT in high-risk patients. 36 
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